March 11, 2025

Michael Breen
Executive Chairman of the Board and Interim Chief Executive Officer
GT Biopharma, Inc.
505 Montgomery Street
10th Floor
San Francisco, CA 94111

       Re: GT Biopharma, Inc.
           Registration Statement on Form S-3
           Filed March 6, 2025
           File No. 333-285618
Dear Michael Breen:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Louis A. Wharton, Esq.